EGFR Signaling in Cancer (2nd Edition)
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: 30 September 2025 | Viewed by 310
Special Issue Editors
Interests: inflammatory breast cancer; triple-negative breast cancer; targeted therapy; signaling pathway; tumor microenvironment
Special Issues, Collections and Topics in MDPI journals
Interests: triple-negative breast cancer; inflammatory breast cancer; bone metastasis; metastatic breast cancer; early drug development
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The epidermal growth factor receptor (EGFR) pathway plays important roles in many cellular processes, including cell growth, differentiation, motility, inflammation, and stem cell biology. The overexpression or mutation of EGFR is associated with the development of various types of cancers, such as breast cancer, lung cancer, glioblastoma, and colorectal cancer. The EGFR pathway regulates tumorigenesis and metastasis through its downstream PI3K/AKT, MEK/ERK, and JAK/STAT signaling. It also regulates the interactions between tumor cells and the surrounding tumor microenvironment. As a result, the EGFR pathway represents an attractive therapeutic target for cancer treatment. Clinical trials of EGFR-targeted therapy with monoclonal antibodies or tyrosine kinase inhibitors have shown efficacy in some cancer types (e.g., lung and colorectal cancers, as well as inflammatory breast cancer). Still, EGFR-targeted therapy is not very effective in other cancer types, and some patients develop drug resistance. It is critical to elucidate the biological function of the EGFR pathway in regulating tumor cells as well as the tumor microenvironment and establish more effective combination therapies with anti-EGFR agents.
This Special Issue will highlight novel findings on different aspects of the EGFR pathway, including, but not limited to, (1) the function of the EGFR signaling pathway in tumors and the tumor microenvironment in different cancer types; (2) the mechanism of resistance to EGFR-targeted therapy and approaches to overcoming this resistance; (3) the development of drugs targeting EGFR and EGFR signaling; and (4) clinical trials of EGFR-targeted therapy in different cancer types. We hope that this Special Issue will advance our understanding of the EGFR pathway in tumor progression, leading to improved treatments and prolonged survival for cancer patients.
Dr. Xiaoping Wang
Prof. Dr. Naoto T. Ueno
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- epidermal growth factor receptor (EGFR)
- tumor microenvironment
- drug resistance
- clinical trial
- cell signaling
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
Related Special Issue
- EGFR Signaling in Cancer in Cancers (7 articles)
